Patients with stage III-IV OPC enrolled onto Radiation Therapy Oncology Group trials @ or RTOG @ who had known tumor p@ status plus local , regional , and/or distant progression after receiving platinum-based chemoradiotherapy were eligible for a retrospective analysis of the association between tumor p@ status and overall survival ( OS ) after disease progression .